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reports from consumers before, even without having an official imple-
mented system for that purpose. Countries with older systems, such as
Netherlands, Denmark and Sweden, have about 21–35 % of reports were
collected directly from patients; On the other hand in some countries the
value is residual.
Conclusion: Patient’ reports became accepted mandatorily by all coun-
tries through European Union, although, their contribution to Pharma-
covigilance is quite variable. The older systems and those who promote
the system have better results in reporting levels. The contribution of
patients for pharmacovigilance is often considered important and useful in
terms of information given and quality of reports, contributing to a better
knowledge and improvement of medicines.
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Mitoxantrone Treatment-Induced Cardiotoxicity
in Patients with Multiple Sclerosis
C. Matos1, D. Martins1, J. Joaquim1
(1) Coimbra Health School, Pharmacy, Coimbra, Portugal
Introduction: Multiple Sclerosis (MS) is a chronic, autoimmune, neu-
rodegenerative and demyelinating disease of the central nervous system,
which affects the quality of life of patients and their families. This disease
is characterized by relapses or exacerbations, which are clinical conse-
quences of increased inflammatory activity in the CNS. Few treatment
options for patients with secondary progressive multiple sclerosis (SPMS)
is available. Mitoxantrone (type II topoisomerase inhibitor) could be used
to treat MS, most notably the subset known as SPMS. Mitoxantrone will
not cure MS, but could be effective in slowing the progression of SPMS
and extending the time between relapses in relapsing-remitting MS and
progressive relapsing MS.
Aim: Systematic assessment of the scientific evidence on the efficacy and
safety of Mitoxantrone use in patients suffering from MS.
Methods: A systematic critical review without meta-analysis was con-
ducted through information collection in electronic databases such as
PubMed, B-On, ScienceDirect, Elsevier and SciELO. Language restriction
to Portuguese, Spanish and English was applied. PICO parameters were
applied and the following keywords were used: Cardiotoxicity, Mitox-
antrone, Multiple sclerosis and Safety. Were selected items with less than
10 years from 2005–2014, full access and interest. The final selection of
relevant items was done by full reading and giving priority to original
articles.
Results: Conventional therapy includes immunomodulatory and
immunosuppressive drugs, which act at different stages of the disease and
reduce the frequency of relapses or exacerbations, control the symptoms
exacerbation and delay long-term disability. The available therapy isn’t
completely safe, due to its adverse effects, however, there are patients who
have an effective response. Many drugs have been investigated to provide
a better quality of life to the patient. Mitoxantrone is an anthracenedione
synthetic agent originally developed for cancer treatment. Preclinical
studies have also shown that mitoxantrone has immunosuppressive prop-
erties, leading to clinical investigation in patients with MS. Currently this
drug is approved in the USA and Europe for the treatment of the most
active MS forms. The use of mitoxantrone, in patients with MS, is asso-
ciated with significant risks, such as cardiotoxicity.
Conclusion: The use of mitoxantrone should be carefully considered, and
doctors should prescribe the smallest possible cumulative dose to reach
clinical effects and desired monitor patients during and after the treatment.
Effectively each administration of mitoxantrone should be accompanied
by monitoring cardiac function to improve the safety of treatment for
patients and enable early detection of any side effects, especially in high
risk groups.
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Compromise of the Effectivity of Oral Contraceptives
in Concomitant Use with Antibiotics
C. Matos1, A. Cruz1, J. Joaquim1
(1) Coimbra Health School, Pharmacy, Coimbra, Portugal
Introduction Oral hormonal contraception is the most widely used
method worldwide for women in preventing unwanted pregnancy by
removing the follicular stimulating hormone (FSH) in the ovarian cycle.
The concomitant use to other drugs could induce hormone blockade.
Among the described medicines, the possible interactions between oral
antibiotics and oral contraceptives (OC) remain a subject that generates
controversy among the scientific community. Co-administration with
potent enzyme inducers of microsomal hepatic metabolism, as rifampicin,
can increase the hepatic catabolism of estrogen or progestogen, reducing
the half-life and respective effectivity.
Aim: To assess the interaction between OC and antibiotics and charac-
terize the mechanisms involved in the effect of the antibiotic therapy with
OC’s.
Methods: A systematic review was conducted from the PubMed, Med-
scape, SciELO. Language restrictions to Portuguese, Spanish and English
were applied. PICO parameters were applied and the following keywords
were used: (patients OR individuals OR person OR women) AND (an-
tibiotics) AND (oral contraceptives) AND (drug interaction) AND (effi-
cacy) AND (pregnancy). Articles were selected based on information
related to antibiotic therapy and OC’s efficacy relationship. A total of 30
articles were selected for analysis.
Results: In 1974, Reimers reported that five of 88 women who used
CO and rifampicin were pregnant. Swenson (1980) found an increased
excretion and reduced half-life plasma of ethinylestradiol in 5 women
taking OC, and 4 were treated with tetracycline and ampicillin More-
over, Back et al. (1990) observed 13 oral contraceptive users women
who were also taking ampicillin and not found hormonal changes in
plasma concentrations compared with previously controlled cycles. The
explanation for these conflicting results may be related to individual
variations in the metabolism of OC. The women may have low
bioavailability of ethinylestradiol due to the extensive metabolism of
steroids in the intestinal wall and liver, large intrahepatic circulation of
ethinylestradiol and intestinal flora particularly susceptible to
antibiotics.
Conclusion: Rifampicin is the only antibiotic scientifically proven inter-
action, to accelerate metabolism of OC, through the induction of CYP450,
leading to decreased effectivity. Most of the analyzed antibiotics
decreased the level or effect of OC indirectly by altering intestinal flora,
remaining a low risk of contraceptive failure. However, the main adverse
reactions reported with the use of antibiotics include: nausea, vomiting
and diarrhoea, which could also have interference on the efficacy of OC’s.
Information to women is essential to manage this interaction and to ensure
the oral contraceptive effectivity.
1004 Abstracts
